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Abstract 
Background. Seasonal influenza is a highly contagious infection that might lead to serious clinical 
complications and incurs a conspicuous socio-economic impact. Influenza vaccination is currently 
recommended only for specific groups of healthy adults (such as healthcare workers) even though it was 
demonstrated to be effective in reducing absenteeism and decreased workers’ productivity during flu epidemic 
period. The main purpose of this study is to analyse the extent of absences due to illness following a voluntary 
flu immunization program among the Komatsu Italia Manufacturing company’s personnel during the flu 
season 2017-2018. Secondly, we aimed at performing a cost-benefit analysis of the vaccination campaign 
from the company’s perspective. 
Study design. This is an observational cohort study conducted during the period between the 14th week of 
2017 and the 13th week of 2018 (from 03/04/2017 to 01/04/2018). The study population was the personnel 
of Komatsu Italia Manufacturing S.p.A. on duty during the study period. 
Methods. For each subject the following data were collected: sex, date of birth, professional profile, seasonal 
influenza immunization status and sick-leave days. Sick-leave days were compared among the influenza 
epidemic period and the previous one between vaccinated and unvaccinated and any difference in days of 
absence was considered to be caused by seasonal influenza.
Results. Out of 408 employees, 60 (14.7%) accepted the voluntary influenza vaccination. In multivariate 
analysis (logistic model) an age ≥ 50 years was the only predictor for vaccination acceptance (OR
M
 3.11 
p<0.001). During the flu period, the monthly mean of sick-leave days per employee was significantly lower 
among the vaccinated than the unvaccinated, respectively of 0.328 days/person vs 0.752 days/person (p = 
0.022). Unvaccinated employees reported a higher average of sick-leave days during the flu period compared 
to the previous non-influenza period (0.752 days/month/person vs 0.337 days/month/person p <0.001). The 
monthly mean cost for sickness absences per employee was significantly higher for an unvaccinated subject 
compared to one vaccinated, respectively € 129.00 and € 54.00 (p = 0.028). The overall net saving estimated 
was € 314.00 per person vaccinated.
Conclusions. Influenza vaccination proved to be an extraordinary preventive tool and a cost-effective 
intervention. However, influenza immunization seems to be unappealing among healthy adults and higher 
flu vaccination coverages could be achieved through educational interventions possibly addressing young 
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Introduction
Seasonal influenza is a highly contagious 
infection caused by different viruses. 
Although in most cases it manifests with 
mild respiratory and systemic symptoms 
and it resolves in few days, occasionally it 
might lead to serious clinical complications, 
such as secondary bacterial pneumonia or 
exacerbations of underlying conditions, 
especially among elderly and vulnerable 
people. However, it represents a considerable 
public health issue since globally it causes 
approximately from 290.000 to 650.000 
deaths each year (1). In Europe seasonal 
influenza accounts for 4-50 million 
cases per year (2) and it affects up to 9% 
of Italian population each year (3). In 
Italy it is monitored through a specific 
surveillance system (Influnet) (4) and entails 
a conspicuous cost estimated in an average 
of 1.3 million euro annually (5, 6). The 
economic impact gets even more relevant 
when considering indirect costs incurred 
by employers, families, National Health 
Service (Servizio Sanitario Nazionale, 
SSN), Italian National Social Insurance 
(Istituto Nazionale Previdenza Sociale - 
INPS) with an overall cost of approximately 
2.86 billion euro (7). In the workplace, 
seasonal influenza demonstrated to cause 
lack of productivity and absenteeism (8, 9), 
with an average of 3.7-5.9 sick leave days 
per influenza episode (10). Modelling of 
transmission estimated that a non-negligible 
percentage of influenza’s transmission 
occurs within the area of employment 
and specific workplace strategies aimed at 
preventing and controlling communicable 
diseases transmission have been proven 
to reduce presenteeism, absenteeism and 
related costs (11). Influenza vaccination is 
certainly among the most effective strategies 
to avert influenza, particularly its severe 
complications among high risk groups, thus 
reducing hospitalizations and deaths (12-14). 
The composition of the flu vaccine is updated 
every year according to the indications 
provided by the World Health Organization 
(WHO) (15, 16).
In Italy, influenza immunization is highly 
recommended for individuals affected by 
chronic illnesses, elderly- people aged over 
65, pregnant women, residents in health and 
social care facilities and personnel who have 
regular contacts with the aforementioned 
individuals (17, 18). 
Currently, influenza vaccination for 
healthy working adults is not suggested 
although it has been proven to reduce the 
incidence of flu syndrome and absences due 
to illness (19-22) and to be cost effective 
even for workers in non-health environments 
(23). Conversely, a recent Cochrane review 
suggested that influenza immunization 
among healthy adults would be just mildly 
effective in preventing cases of confirmed 
flu and flu-like syndrome (24).
The economic convenience is mostly 
related to the indirect costs of lost productivity 
(25) with a stable relationship between the 
benefits of flu vaccination and the indirect 
costs of absenteeism at work (26). At 
European level it was estimated that a 75% 
coverage with influenza vaccine would have 
avoided 72.6 million euro in direct costs 
and 112 million euro in indirect costs (27). 
However, as economic assessments still 
have some limitations and the benefit of 
extending flu immunization to healthy adult 
workers remains unclear, any evaluation is 
let at the discretion of each individual and 
employer, as they are the major beneficiaries 
of workplace vaccination campaign (24).
employees who showed little interest in vaccination. Finally, among health promotion interventions, 
companies should point out the importance of flu vaccination both for the individual wellbeing and the 
company environment.
236 A. Ferro et al.
The main purpose of this study is to 
analyse the extent of absences due to illness 
following a voluntary flu immunization 
program among the Komatsu Italia 
Manufacturing company’s personnel during 
the flu season 2017-2018. Secondly, we 
aimed at performing a cost-benefit analysis 
considering the absenteeism’s economic 
impact and the vaccination campaign’s cost 
from the company’s perspective. 
Methods
Study design and subjects
This is an observational cohort study 
about a voluntary vaccination program and 
it was conducted during the period between 
the 14th week of 2017 and the 13th week of 
2018 (from 03/04/2017 to 01/04/2018).
The study population was the personnel 
of Komatsu Italia Manufacturing S.p.A. on 
duty during the study period. Komatsu Italia 
Manufacturing S.p.A. is an agricultural 
machinery company located in Este (Padua, 
Italy) with 408 employees including 
workers and other staff employed. In 
January 2015, thanks to the cooperation 
between the company’s board and the 
Prevention Department of South Padua 
District - Euganea Local Health Unit 
(ULSS) 6 - a three-year project on health 
promotion at the workplace was started. In 
addition to several interventions addressed 
to the adoption of healthy lifestyles (such 
as proper nutrition, smoking cessation, 
regular physical activity, lower alcohol 
consumption and stress management), a 
voluntary influenza immunization program 
was implemented. In October 2017, all 
employees were informed about the 
influenza vaccination program and correctly 
instructed about the disease, purpose of 
vaccination, indications, contraindications 
to vaccinations and potential adverse 
effects. Influenza trivalent vaccine (Infanrix 
Hexa®) was offered free of charge and it 
was administered by a medical doctor at 
the medical practice of the company in two 
times during November 2017. Eligibility 
for vaccination was screened based on 
predefined criteria (no history of immediate 
hypersensitive reaction, absence of any 
acute illnesses or symptoms). 
According to current Italian legislation an 
informed consent was not required (28).
Data collection and management
For each subject the following data were 
collected: sex, date of birth, professional 
profile, seasonal influenza immunization 
status and sick-leave days. The data were 
obtained by the company’s Human Resources 
Office. All data were anonymized, giving 
each subject a progressive numerical code 
(29). All the results of the analysis were 
reported as aggregated data so that they 
could not be attributed, either directly or 
indirectly, to the individual subject.
Sick-leave days referred to absences 
for all-illnesses causes since the diagnosis 
codes were not accessible to the company, 
as imposed by Italian privacy law.
Considering the influenza incidence rates, 
reported by the regional surveillance (30), 
within the study period were identified the 
followings: a non-epidemic period from 
week 14th to 46th 2017 (i.e. from 03/04/2017 
to 19/11/2017), and a flu epidemic period 
from week 47th 2017 to week13th 2018 
(from 20/11/2017 to 01/04/2018). The non-
epidemic period lasted 33 weeks and it was 
used as baseline, whereas the subsequent flu 
period lasted 19 weeks. Sick-leave days were 
compared among the two periods (for the 
non-influenza baseline period only working 
days were considered) and any differences 
in days of absence considered to be caused 
by flu epidemic.
Cost-benefit analysis
For the cost-benefit analysis, the saving 
was computed as the difference between the 
immunization program cost and the money 
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made between vaccinated and unvaccinated 
employees.
The degree of association between the 
Incident Rate Ratio (IRR) of sick leave 
days during the epidemic period and the 
vaccination condition was assessed by 
a multivariate negative binomial model 
considering the following covariates: 
vaccination status, sex, age and professional 
profile. 
Sick leave days and related costs incurred 
by the company were compared between 
vaccinated and unvaccinated using the Two-
sample Wilcoxon rank-sum test and between 
flu and non-flu period using the Wilcoxon 
signed-rank test. In all the analyses carried 
out a p-value value <0.05 was considered 
significant. The data were analysed with the 
Stata software version 14 (Stata Corporation, 
College Station, TX, USA).
Results
Out of 408 employees, 60 (14.7%) 
accepted the voluntary influenza vaccination. 
The socio-demographic characteristics of 
the subjects according to vaccination status 
are summarized in Table 1. Among the 
vaccinated participants, 25 had duties related 
to “administration” or “production line” 
whereas 35 had a “manager” professional 
profile. The vaccinated subjects were older 
than the unvaccinated ones (aged 50-69 
years vs < 50 years; p <0.001) and mostly 
employed in management duties (p = 
0.026).
In multivariate analysis (logistic model) 
an age ≥ 50 years was the only predictor for 
vaccination acceptance (OR
M
 3,11 p<0.001) 
(Table 2). 
During the influenza period the monthly 
mean of sick leave days per employee was 
significantly lower among the vaccinated 
than the unvaccinated, respectively 0.328 
days/person vs 0.752 days/person (p = 
0.022). Unvaccinated employees reported 
saved thanks to the absences prevented by 
vaccination (31). 
The company covered the entire cost 
of the immunization program. The cost of 
vaccination was € 13 per dose (€ 2.30 with 
VAT at 10% for the vaccine purchase and € 
10.00 for the service).
The data regarding sick-leave costs 
were provided by the company. Regardless 
of the professional profile, each working 
day accounts for eight working hours. 
Each sick-leave hour incurs a direct cost 
for the company equal to € 24.76 for 
individuals employed in administration 
duties or involved in the production line 
and a cost equal to € 35.58 for all other 
professional profiles (such as manager 
profile). According to Italian legislation, 
after the fourth day of absence (considering 
both working days and weekend days), the 
sick-leave cost for “worker” profile is half 
covered by the National Institute of Social 
Security (INPS) (32). Differently, for all 
other employee profiles, the sick-leave 
costs are entirely charged to the company. 
The hourly costs derive from the sum of 
the direct costs due to: basic remuneration, 
extraordinary remuneration, related social 
contributions, holiday pay and severance 
indemnity. The indirect costs at the expense 
of the company caused by either absenteeism 
or presenteeism were not calculated.
Statistical analysis
Demographics and professional profile 
characteristics of employees among those 
vaccinated and unvaccinated were compared 
using descriptive statistics. Chi-squared 
test, or fisher test when appropriate, were 
used for analysing categorical variables and 
student’s t-tests for continuous variables. A 
logistic regression model was fit to evaluate 
the association between covariates and 
vaccination acceptance.
Incidents rates (IR) of sick-leave days 
per person per week during the flu period 
were calculated and comparisons were 
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Table 1 - Demographics of the study population employed in the Komatsu Manufacturing S.p.A. according to vacci-








n % n % n %
Gender     
female 5 6 17 94.4 18 100.0  0.492
male 59 15.1 331 84.9 390 100.0  
Age (yr)       
18-49 19 8.3 210 91.7 229 100.0 0.000 
50-69 41 22.9 138 77.1 179 100.0  
Duty area       
manager 9 28.1 23 71.9 32 100.0 0.026 
worker/ employee 51 13.6 325 86.4 376 100.0  
Sick-leave days, no-flu period (mean ± sd) 0.48 ±1.315 0.34 ±1.231 0.36 ±1.246 0.238
Sick-leave days, flu period (mean ± sd) 0.33 ±0.780 0.75 ±1.774 0.69 ±1.671 0.022
Table 2 - Predictors of influenza vaccination acceptance 






95% CI p value
Sesso    
Female 1.00   
Male 1.80 0.23 – 4.28 0.575
Age (yrs)    
18-49 1.00   
50-64 3.11 1.72 – 5.62 0.000
Duty    
Manager 1.00   
Worker/Employee 0.45 0.19 – 1.06 0.069
a higher average of illness absence during 
the flu period compared to the previous non-
influenza period (0.752 days/month/person 
vs 0.337 days/month/person p <0.001). The 
variation in the monthly mean of days of 
illness absence between the non-influenza 
period and the flu period is significantly 
different between vaccinated and non-
vaccinated (respectively +0.416 days/person 
and -0.152 days/person; p = 0.0239). 
The incidence rate (IR) of sick-leave 
days per week, among vaccinated and 
unvaccinated, during both the epidemic and 
non-epidemic period, as well as the Incident 
rate ratios (IRR) for the vaccinated are 
reported in Table 3.
Table 3 - Incidence rate (IR) per 1.000 person/week among vaccinated and unvaccinated subjects, during the influenza 
























Incidence Rate Ratio Raw (IRR
R
), Incidence Rate Ratio Adjusted* (IRR
A
). 
*considering the followings: age, vaccination status, gender, professional profile.
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During the epidemic flu period the 
vaccinated reported a lower IR of sick-leave 
days compared to the unvaccinated with 
an incidence difference of –97.6 per 1000 
person-week. 
In multivariate analysis (negative 
binomial model) the IRR
A
 of sick-leave days 
during influenza period for the vaccinated 
was confirmed as significant with a value 
of 0.441 (p=0,022) and duties related to 
administration or production line (compared 
to the manager profile) resulted significantly 
associated to the incidence of days of absence 
(IRR = 2.42, p <0.001) (Table 4). 
As regards the costs analysis due to 
illness absenteeism, the sick leave days and 
relative costs in both periods are described in 
Table 5. The costs reported were computed 
considering the hourly cost per person taking 
into consideration each employee specific 
professional profile.
The monthly mean cost for sickness 
absenteeism per employee was significantly 
higher for an unvaccinated subject compared 
to one vaccinated, respectively € 129.00 and 
€ 54.00 (p = 0.028).
Regardless of the professional profile, 
during the epidemic period the company 
covered an average cost for illness 
absenteeism of € 236 per vaccinated 
employee and of € 563 per unvaccinated 
employee. Thus, exclusive of vaccination 
costs (€13/person), the net saving estimated 
was € 314 per person vaccinated.
Considering specific job profile, during 
the flu period the company spent € 289 per 






95% CI p value
Vaccination   
no 1.00  
yes 0.44 0.22 – 0.89 0.022
Gender   
female 1.00  
male 0.47 0.14 – 1.63 0.237
Age (yrs)   
18-49 1.00  
50-64 1.01 0.62 – 1.66 0.967
Duty   
Manager 1.00  
Worker/employee 2.42 1.43 – 4.08 0.001
Table 5 - Sick leave days and related costs – labour costs only, by vaccination status.
Vaccinated (N=60) Unvaccinated (N=348) All workers (N=408)
Sick leave days Costs Sick leave days Costs Sick leave days Costs
Flu period 220 34,536 € 894 170,737 € 1,114 205,273 €
Non-flu period 86 14,161 € 1,144 195,921 € 1,230 210,082 €
Entire study period 306 48,697 € 2,038 366,658 € 2,344 415,355 €
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worker/administrative employee and € 381 
per manager.
Since influenza immunization campaign 
entailed € 780 cost, multiplying the net 
saving per person for the number of 
participants vaccinated, considering also 
their professional profiles, the company 
overall saved € 19,674.
Discussion 
Seasonal influenza immunization appears 
to be considered mostly unappealing among 
healthy adults who probably do not deeply 
acknowledge and appreciate its potential 
benefits. In our cohort study voluntary 
influenza vaccination was accepted by 
approximately 15% of company personnel 
similarly to other immunization coverage 
achieved among other cohorts of Italian 
workers, particularly among healthcare 
workers (33-37). As already reported by 
other surveys, older workers are more likely 
to get vaccinated probably due an increased 
perceived risk and greater awareness and 
care of their own health (19, 20, 38). 
Seasonal influenza demonstrated to 
deeply affect also healthy adults and, 
according to our results, flu period proved 
to be associated with a notable increase 
in absenteeism among employees (8-10). 
Particularly, a relevant increase (more than 
doubled) in sick-leave days was reported for 
unvaccinated subjects during the epidemic 
period compared to the previous one. 
Certainly, as we lacked data regarding 
specific diagnosis, the assumption that sick-
leave days surplus compared to the previous 
non-flu period could be due to influenza is 
an hypothesis, but we are confident it could 
be quite reliable given the difference in 
average sick-leave days between vaccinated 
and unvaccinated comparing the flu period 
with the previous one. Influenza vaccination 
revealed to be an effective preventive 
strategy capable of reducing days of absence 
due to illness thus confirming the literature 
data (23, 25, 38). Indeed, in our cohort of 
study, vaccinated subjects during the flu 
period reported significantly lower average 
of sick-leave days per person compared to 
the unvaccinated ones. Similarly, another 
Italian study carried out among personnel of 
a research institute reported a lower number 
of days of absence among the vaccinated 
employees (25) and according to a recent 
review influenza vaccination could reduce 
absenteeism by approximately 0.15-3 
days per employee (24). Independently of 
demographic characteristics and professional 
profile, vaccinated personnel showed a halved 
probability of incidence of sick-leave days 
during the flu epidemic period. Moreover, 
workers or administrative employers have a 
likelihood of absenteeism more than doubled 
compared to managers, without regard of 
immunization status and other demographics 
(age and gender). Apparently, this might 
imply that those duties might lead to an 
increased risk of acquiring or transmitting 
infection or that manager’s duties could be 
carried out notwithstanding mild symptoms. 
Although lack of confirmed influenza 
diagnosis represented a relevant limitation, 
we appraised a measure of flu vaccination 
effectiveness in reducing absenteeism due to 
illness suggesting that vaccinated employees 
had a 56.4% reduction (IRR=0.44) in sick-
leave days following vaccination. Whilst, 
considering the entire cohort of study 
population, a 14.7% flu vaccination coverage 
proved an 8.3% efficacy in reducing the days 
of absence. 
People accepting vaccination are usually 
more concerned in their health status and 
adopt more carefully healthy lifestyles. 
However, we can reasonably reject that this 
sort of selection bias might have influenced 
our results, since those participants who 
accepted flu vaccination, in the previous non-
epidemic period had shown a significantly 
higher incidence of absenteeism compared 
to the ones unvaccinated. Therefore, not 
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only can we exclude that they had been 
healthier, but we can also dare to suggest that 
they had been more “fragile” or exposed to 
risk conditions (for instance being in close 
contact with young kids) and then more 
prone to get vaccinated. 
As regards the cost-benefit evaluation, 
performed from company perspective, the 
influenza vaccination campaign confirmed 
to be a cost-effective intervention (21, 
23, 39). In our study, it proved to be 
extraordinarily advantageous, allowing a 
significant reduction of absenteeism and 
therefore generate a saving of up to 300 € per 
employee vaccinated, considering only the 
direct costs. Supposedly, the gain would have 
been even more remarkable if indirect costs 
due to slowed down production line as well 
as delayed goods deliveries were accounted. 
Furthermore, we did not comprise direct 
costs for healthcare incurred by National 
Health Service along with the burden for 
families and civil society itself.
Influenza thus endorsed its considerable 
negative impact on labor market in terms of 
absenteeism, productivity loss and related 
costs causing a conspicuous economic 
burden for the specific company, amounting 
to at a total cost of 210,083 euros for 
the 1,230 total days of sick-leave for all 
employees.
Seasonal influenza entails for companies 
a relevant economic burden that could 
be at least partially averted by increasing 
immunization coverage. Some studies 
reported reductions of more than 80% of 
sick leave days during flu period compared 
to the previous one thanks to flu vaccination 
coverage even slightly above 50% (21, 38). 
In our study cohort, if we had a 50% flu 
vaccination coverage we estimate further 
savings of more than 45,000 euros. A higher 
flu vaccination coverage might be achieved 
through educational interventions stressing 
the importance of immunization and possibly 
specifically addressing younger employees 
who showed little interest in vaccination 
(40) and workers. Furthermore, in order to 
increase adherence to influenza vaccination 
as a preventive tool in the workplace, the 
occupational competent doctor of each 
company could play a leading role in 
providing adequate information.
This study has some limitations: (1) 
exposure misclassification: since we did 
not obtain information regarding factors 
that might have influenced vaccination 
acceptance such as health status, previous 
flu vaccination, personal medical history 
and personal health attitude; (2) effect 
misclassification giving the lack of specific 
diagnosis, some other pathological conditions 
might have caused illness absenteeism. For 
instance, long-term absences are more likely 
to be caused by illnesses other than influenza 
such as surgical interventions and subsequent 
rehabilitation, neoplastic diseases or mental 
diseases such as depressive syndromes; (3) 
in the cost analysis we did not consider the 
indirect costs caused by the slowing down 
of the entire production chain due to the 
absence of personnel, as well as those due 
to presenteeism (i.e. reduced productivity of 
mildly sick employees at work) (11). 
Although influenza vaccination at 
the workplace definitely appears to be a 
cost-effective intervention with important 
organizational and managerial advantages 
for the company perspective, it might 
also result in undeniable profits for each 
employee. Indeed, for each individual himself 
immunization could provide considerable 
personal health and economic advantages 
thanks to the reduction of illness days. 
Moreover, the employee could benefit from 
a healthier workplace, with reduced viruses’ 
circulation and risk of infection transmission 
and take advantage of the economic welfare 
of its own company.
To conclude, we firmly consider the 
workplace as an important environment for 
health promotion interventions allowing 
to target healthy adults otherwise hard to 
access and to raise their awareness regarding 
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health issues. Moreover, during health 
education interventions the importance of 
flu vaccination should be stressed. Given 
our findings, it would be desirable for 
companies, besides investing in health 
education campaigns also to point out the 
importance of flu vaccination for both the 
individual and the company environment.
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Riassunto
Vaccinazione antinfluenzale e assenze per malattia 
in ambiente di lavoro: analisi costo beneficio
Premessa. L’influenza è un’infezione altamente 
contagiosa con possibili gravi complicanze cliniche che 
comporta ingenti costi socioeconomici. La vaccinazione 
antinfluenzale è attualmente raccomandata per gli adulti 
sani in età lavorativa solo per alcune categorie a rischio 
(es. operatori sanitari) sebbene si sia dimostrata efficace 
nel ridurre l’assenteismo e la perdita di produttività dei 
lavoratori nel corso dell’epidemia influenzale. Lo scopo 
dello studio è analizzare l’entità e i costi delle assenze 
per malattia del personale dell’azienda Komatsu Italia 
Manufacturing in relazione alla vaccinazione antinfluen-
zale, nella stagione influenzale 2017-2018.
Disegno dello studio. Lo studio è di tipo osservazio-
nale di coorte. La popolazione in studio è il personale 
dipendente dell’Azienda Komatsu Italia Manufacturing 
S.p.A. in servizio (senza interruzioni) nel periodo com-
preso tra la 14° settimana del 2017 e la 13° settimana del 
2018 (ovvero dal 01/04/2017 al 01/04/2018). 
Metodi. Per ciascun soggetto sono stati raccolti i se-
guenti dati: sesso, data di nascita, profilo professionale, 
condizione di vaccinazione antinfluenzale e giorni di 
assenza per malattia. Sono stati confrontati i giorni di 
assenza del periodo di epidemia influenzale con quelli del 
precedente periodo non epidemico, tra dipendenti vacci-
nati e non vaccinati, ed eventuali differenziali dei giorni di 
assenza sono stati attribuiti all’epidemia influenzale. 
Risultati. La vaccinazione antinfluenzale è stata 
accettata dal 14.7% dei dipendenti cui è stata offerta 
(60/408). Durante il periodo influenzale, i dipendenti 
vaccinati hanno riportato una media di giorni di assenza 
per dipendente significativamente inferiore di quelli 
non vaccinati (0.328 giorni vs 0.752 giorni; p=0.022). 
I dipendenti non vaccinati hanno riportato una media 
di giorni di assenza per dipendente significativamente 
maggiore durante il periodo influenzale rispetto al non 
influenzale (0.752 vs 0.337 p<0.001). Un’età ≥ 50 anni 
è risultata l’unico fattore predittivo per la vaccinazione 
(OR
M
 3.07 p<0.001). Il rischio relativo di incidenza di 
giorni di assenza (Incident rate ratio -IRR) è risultato 
0.436. Il costo medio per assenze per dipendente al 
mese è risultato maggiore per un soggetto non vaccinato 
rispetto ad uno vaccinato,  rispettivamente € 129.00 e 
€ 54.00 (p=0,028). Complessivamente la campagna di 
vaccinazione ha consentito un risparmio netto di € 314.00 
per dipendente vaccinato e un risparmio complessivo per 
l’azienda di  € 19.674. 
Conclusioni. La vaccinazione si è dimostrata uno 
straordinario strumento preventivo in grado di ridurre 
significativamente i giorni di assenza durante il periodo 
influenzale comportando per l’azienda un risparmio 
notevole a fronte dei costi sostenuti per la campagna 
vaccinale. La vaccinazione antinfluenzale si dimostra 
quindi un intervento costo-efficace per l’azienda. Sarebbe 
auspicabile che le aziende, nell’ambito degli interventi 
di promozione alla salute, sottolineassero l’importanza 
della vaccinazione antinfluenzale per il benessere sia 
dell’individuo che dell’azienda. In particolare, interventi 
educativi più specificamente rivolti ai lavoratori più gio-
vani potrebbero consentire di raggiungere coperture vac-
cinali antinfluenzali maggiori nelle coorti di lavoratori. 
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